Home › Compare › DNPCF vs ABBV
DNPCF yields 1.42% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, DNPCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DNPCF + ABBV for your $10,000?
Dai Nippon Printing Co., Ltd. primarily engages in the printing business. The company's Information Communication segment offers books and magazines; flyers and catalogs; business process outsourcing services; solar-powered outdoor LCD digital signage/universally designed touch screen multilingual signage; extended reality communication and virtual reality products, business forms, smart cards and magnetic cards, and transparent hologram ribbons; and dye-sublimation thermal transfer printing media and thermal mass transfer printing media, dye-sublimation photo printers, photo related services and solutions, and identity verification services, as well as operates hybrid bookstore network under honto brand. Its Lifestyle and Industrial Supplies segment provides packaging products comprising plant-based packaging materials, mono-material packaging materials, transparent vapor deposition films, barrier paper packaging materials, functional film complex PET bottles, PET plastic bottles, and aseptic filling systems for PET plastic bottles; living spaces products, including olefin-based sheets for flooring, antibacterial and antiviral products, exterior materials for buildings, curved resin glazing, interior coverings for railway cars; and industrial high-performance materials that include lithium-ion battery and photovoltaic module components, lighting films, and multifunctional insulation boxes. The company's Electronics segment offers optical and electrode films, OLED display, color filters, electronic shade, transparent screens, and OLED display-driven digital signage products; and electronic devices comprising semiconductor photomasks, master template for nanoimprinting, hard disk drive suspensions, lead frame for compact semiconductor packages, diffractive optical element, near field communication modules, and micro electro mechanical systems. Its Beverages segment produces and sells beverages. The company was founded in 1876 and is headquartered in Tokyo, Japan.
Full DNPCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.